Study wrapper · #962
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Yamauchi T, Becker NP, Hagemann CA, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(25)00402-4PubMed: 42009015
Editor's note
This is a well-powered phase 3a randomized active-controlled trial (REDEFINE 5) comparing fixed-dose cagrilintide-semaglutide against semaglutide alone in an east Asian population. The combination was associated with significantly greater weight loss at 68 weeks, with a comparable and predominantly gastrointestinal adverse-event profile. As a rigorous head-to-head RCT on two tracked peptides it is high-value evidence, reported as association.
Plain-language abstract
In a phase 3 trial of 331 east Asian adults, the cagrilintide-semaglutide combination was associated with about 18% weight loss at 68 weeks versus about 12% with semaglutide alone, with similar rates of mostly gastrointestinal side effects.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026